PIN69 - Combining Disease Transmission and Numbers Treated in Conventional Cost-Effectiveness Analyses of Hepatitis C Treatment In the UK

P Mcewan,H Bennett Wilton,S Webster,A Kalsekar,Y Yuan,M Brenner

doi:10.1016/j.jval.2015.03.1393

PIN69 - Combining Disease Transmission and Numbers Treated in Conventional Cost-Effectiveness Analyses of Hepatitis C Treatment In the UK

P Mcewan, H Bennett Wilton + Show 4 more

Open Access

https://doi.org/10.1016/j.jval.2015.03.1393

Copy DOI

Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research	Publication Date: May 1, 2015
License type: elsevier-specific: oa user license

Affiliation: Health Economics and Outcomes Research (United Kingdom), Bristol-Myers Squibb (United States), Bristol-Myers Squibb (United Kingdom)

#International Society For Pharmacoeconomics And Outcomes Research #Pharmaceuticals Ltd + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

This research was funded by Bristol-Myers Squibb Pharmaceuticals Ltd. Presented at the 20th annual meeting of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), May 16-20th 2015, Philadelphia, USA. • Chronic infection with the hepatitis C virus (HCV) can lead to end-stage liver disease (ESLD) complications including decompensated cirrhosis (DC) and hepatocellular carcinoma (HCC) [1-3].

Full Text